georges Bahr | Immunology | Innovative Research Award

 

Innovative Research Award

              Georges Bahr
Researcher Georges Bahr
Affiliation University of Balamand
Country Lebanon
Scopus ID 7102520346
Documents 116
Citations 2,560
h-index 28
Subject Area Immunology
Event International Molecular Biologist Awards

Georges Bahr

University of Balamand, Lebanon

Georges Bahr is affiliated with the University of Balamand in Lebanon and has an indexed research profile in the field of immunology. The Innovative Research Award recognizes researchers whose scholarly work demonstrates sustained scientific activity, originality, and measurable contribution to their respective fields. According to the supplied Scopus profile information, the researcher has 116 documents, 2,560 citations, and an h-index of 28.[1]

Abstract

Georges Bahr’s academic profile reflects an established research record in immunology, supported by a substantial body of indexed scholarly publications and measurable citation activity. The supplied bibliometric data identify 116 documents, 2,560 citations, and an h-index of 28. These indicators provide quantitative evidence of research visibility and scholarly influence, while qualitative assessment of individual publications remains important when evaluating scientific innovation and significance.[1][2]

Keywords

Immunology, Molecular Biology, Cellular Immunology, Immune Response, Biomedical Research, Scientific Publications, Research Impact, Citation Analysis, Translational Research, Academic Excellence.

Introduction

Immunology is a multidisciplinary area of biomedical science concerned with the study of immune-system components, immune responses, host–pathogen interactions, inflammation, and mechanisms underlying immune-mediated disease. Contemporary immunological research frequently integrates molecular biology, cellular biology, genetics, microbiology, and clinical science to investigate mechanisms operating at multiple biological scales.[3]

Academic research profiles in immunology may be assessed using both qualitative and quantitative measures. Bibliometric indicators, including publication counts, citation counts, and the h-index, can provide useful contextual information regarding scholarly dissemination and influence, although they do not independently establish the scientific quality of individual studies.[2][4]

Research Profile

Georges Bahr is associated with the University of Balamand, Lebanon, and is represented in Scopus under author identifier 7102520346. The supplied profile records 116 documents and 2,560 citations, with an h-index of 28. These figures indicate a sustained publication record and citation presence within the indexed scholarly literature.[1]

  • Institutional affiliation: University of Balamand.
  • Country: Lebanon.
  • Primary subject area: Immunology.
  • Scopus author identifier: 7102520346.
  • Indexed documents: 116.
  • Reported citations: 2,560.
  • Reported h-index: 28.

Research Contributions

Research in immunology contributes to understanding the molecular and cellular mechanisms responsible for immune recognition, regulation, inflammation, host defense, and immune-associated disorders. Within this broad discipline, scholarly contributions can encompass experimental investigation, molecular characterization, cellular studies, disease mechanisms, and translational approaches. The available profile information establishes Georges Bahr’s disciplinary classification but does not provide sufficient evidence to assign specific individual discoveries or mechanisms without reviewing the underlying publications.[1][3]

The combination of publication activity and citation accumulation provides an indication that the researcher’s work has been disseminated within the scholarly literature. Detailed evaluation of originality, methodological rigor, reproducibility, and practical significance should be conducted at the publication level by subject-matter experts.[4]

Publications

The supplied Scopus information records 116 documents associated with Georges Bahr. Scopus provides bibliographic and citation information that can be used to examine publication output, citation patterns, collaboration, and subject-area distribution. Individual publication titles, journal details, publication years, and DOI identifiers should be verified directly through the corresponding bibliographic records before being used for detailed publication analysis.[1]

  • Total documents reported in the supplied Scopus profile: 116.
  • Research classification: Immunology.
  • Publication-level DOI information should be verified against individual source records.

Research Impact

The supplied bibliometric profile reports 2,560 citations and an h-index of 28. The h-index was introduced as a measure intended to combine aspects of publication productivity and citation impact, with the value representing a set of publications that have each received at least the corresponding number of citations.[4]

Citation indicators should be interpreted within disciplinary and temporal context because citation practices vary substantially among research fields, publication types, and career stages. Consequently, bibliometric metrics are most appropriately considered alongside peer assessment, research quality, originality, methodological strength, and broader scientific contribution.[2][5]

Award Suitability

The supplied academic indicators provide a quantitative basis for considering Georges Bahr within an award evaluation framework. A record of 116 indexed documents, 2,560 citations, and an h-index of 28 demonstrates sustained scholarly activity and measurable citation impact according to the supplied Scopus data.[1]

For the Innovative Research Award, further evaluation may consider the originality of research questions, significance of findings, methodological innovation, interdisciplinary contribution, reproducibility, mentoring, collaboration, and influence on subsequent research. Final award decisions should remain subject to the applicable eligibility criteria and independent assessment procedures of the International Molecular Biologist Awards.

Conclusion

Georges Bahr, affiliated with the University of Balamand in Lebanon, has a documented scholarly profile in immunology with 116 reported Scopus-indexed documents, 2,560 citations, and an h-index of 28. These indicators demonstrate sustained research activity and measurable scholarly visibility. A comprehensive assessment of research excellence should additionally consider the quality, originality, significance, and reproducibility of the underlying scientific work.[1][2]

References

  1. Elsevier. (n.d.). Scopus author details: Georges Bahr, Author ID 7102520346. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=7102520346
  2. Elsevier. (n.d.). Scopus: Abstract and citation database for peer-reviewed literature. Scopus.
    https://www.scopus.com/
  3. Murphy, K., & Weaver, C. (2016). Janeway’s Immunobiology (9th ed.). Garland Science.
    https://doi.org/10.1201/9781315533247
  4. Hirsch, J. E. (2005). An index to quantify an individual’s scientific research output. Proceedings of the National Academy of Sciences, 102(46), 16569–16572.
    https://doi.org/10.1073/pnas.0507655102
  5. International Molecular Biologist Awards. (n.d.). Official Award Website.
    https://molecularbiologist.org/

Alessia Muzi | Immunology | Women Researcher Award

Dr. Alessia Muzi | Immunology | Women Researcher Award

Principal investigator | Takis srl | Italy

Dr. Alessia Muzi is an accomplished Italian scientist and Principal Investigator at Takis Srl, leading pioneering research in oncology, monoclonal antibody engineering, and translational biotechnology. With over 20 years of experience, she has contributed significantly to therapeutic antibody development, vaccine innovation, and cancer immunotherapy. She holds a Ph.D. in Neurosciences from the University of Sacred Heart “Agostino Gemelli” and advanced degrees in Medical Biotechnology and Regulatory Medicine from the Universities of Rome “Tor Vergata” and “Sapienza.” As Head of the Monoclonal Antibody Laboratory at Takis, Dr. Muzi oversees cutting-edge projects focused on recombinant protein design and tumor-targeting antibodies. Her research bridges molecular biology and clinical applications, aiming to enhance the efficacy of cancer treatments and immunotherapies. Recipient of the FISA-2022-00899 Award for bispecific antibody development, she has co-authored 33 publications with an h-index of 20 and 1,121 citations across 1,018 documents. Dr. Muzi’s scientific leadership, regulatory expertise, and commitment to translational medicine have established her as a leading figure in Italian biomedical innovation and a driving force in advancing therapeutic strategies for oncology and infectious diseases.

Profile: Scopus | ORCID

Featured Publications

Novel Humanized Anti-HER3 Antibodies: Structural Characterization and Therapeutic Activity. (2025). Antibodies. Cited by 12.

Isolation and Characterization of Neutralizing Monoclonal Antibodies Against SARS-CoV-2 Spike Protein. (2024). Antibodies. Cited by 25.

A Linear DNA Vaccine Candidate Encoding SARS-CoV-2 RBD in Domestic Cats. (2023). Mol Ther Methods Clin Dev. Cited by 9.

A First-in-Human Trial of COVID-eVax DNA Vaccine. (2022). Mol Ther. Cited by 40.

Persistent B Cell Memory After SARS-CoV-2 Vaccination. (2022). Cell Host Microbe. Cited by 58.

COVID-eVax: Electroporated DNA Vaccine Candidate Encoding SARS-CoV-2 RBD. (2022). Mol Ther. Cited by 65.

The Nuts and Bolts of SARS-CoV-2 Spike RBD Heterologous Expression. (2021). Biomolecules. Cited by 33.

Qibin Liao | Immunology | Best Researcher Award

Dr. Qibin Liao | Immunology | Best Researcher Award 

Assistant Researcher, at Shenzhen Third People’s Hospital, China.

Dr. Qibin Liao (b. February 1991 🇨🇳) is a leading early-career biomedical researcher specializing in cellular immunotherapy for infections and malignancies. Currently an Assistant Researcher at Shenzhen Third People’s Hospital, affiliated with the Southern University of Science and Technology, he focuses on the development of next-generation CAR-T cell therapies. His pioneering work includes genetically engineered T-cell technologies, including multifunctional CAR-T cells for HIV-1, and novel systems for solid tumors that improve safety and efficacy. Dr. Liao’s contributions have been widely recognized in high-impact journals such as EMBO Molecular Medicine, Biomedicines, and Cell Discovery. 🧪🔬 His research continues to push the boundaries of precision immunotherapy, bridging basic science and clinical application. He has also been awarded substantial national-level research funding and plays critical roles in multiple R&D programs. Through innovative designs and clinical translation, he is reshaping the future of personalized medicine and cancer treatment. 🌍💉

Professional Profile

Scopus

ORCID

🎓 Education

Dr. Qibin Liao began his academic journey at Southern Medical University where he earned a Bachelor of Medicine in Preventive Medicine (2010–2015). His strong foundation in public health and disease prevention laid the groundwork for his later focus on translational immunotherapy. 🚑🧠 He further advanced his training by pursuing a Ph.D. in Medical Systems Biology at Fudan University (2015–2021), one of China’s top-tier research institutions. Here, he honed his expertise in systems-level analysis and experimental techniques related to T-cell engineering and immunological signaling. His doctoral research contributed to the development of hypoxia-inducible CAR-T systems—a novel approach to improve safety and specificity in cancer therapy. 🎓💉 His interdisciplinary education spanning clinical medicine, biology, and biotechnology enables him to approach complex immunological problems with a holistic and systems-oriented mindset. This strong academic foundation underpins his contributions to advanced biomedical innovations.

💼 Professional Experience

Since October 2021, Dr. Liao has served as an Assistant Researcher at Shenzhen Third People’s Hospital, the Second Affiliated Hospital of Southern University of Science and Technology. 🏥 He is part of an elite biomedical team addressing viral infections, immune therapies, and tumor immunology. His role includes designing synthetic CAR-T constructs, leading clinical translational research, and supervising junior researchers in immunotherapy development. 💡 Before this, his graduate training involved active participation in interdisciplinary immunology and molecular biology labs at Fudan University, where he collaborated on multiple clinical and preclinical studies. His career is marked by a strategic blend of basic science and applied therapeutic innovation. Dr. Liao also serves as Principal Investigator (PI) and co-leader in several national programs funded by the National Natural Science Foundation of China and National Key R&D Program, demonstrating both scientific leadership and administrative excellence. 🧪📊

🔬 Research Interests

Dr. Liao’s research centers on cellular immunotherapy, particularly CAR-T cell technology tailored for HIV-1 and solid tumors. 💉 His key interest lies in genetic engineering of T cells to enhance therapeutic performance while minimizing toxicity. He has pioneered techniques such as the hypoxia-inducible CAR-T (HiCAR) system and PD-L1 chimeric costimulatory receptors, designed to address safety challenges in treating solid malignancies. 🧠 His research also extends to multifunctional CAR-T designs with dual antiviral and antitumor capabilities, applied in phase I clinical studies. Dr. Liao is passionate about immune microenvironment modulation, tumor-selective antigen targeting, and developing biomarker-based predictive tools for personalized therapy outcomes. 🧬 His projects integrate synthetic biology, translational immunology, and clinical oncology, making his research deeply impactful for both infectious diseases and cancer immunotherapy. His vision is to bring precision immune-engineering tools from bench to bedside. 🧑‍🔬🦠

🏆 Awards

🔹 Best Researcher Award Nomination (2025) – Selected for publication in Biomedicines (2025) for innovative CAR-T therapy targeting AXL in solid tumors.
🔹 National Natural Science Foundation of China (NSFC) – Youth Science Fund Grant (¥300,000, 2025–2027).
🔹 National Key R&D Program Grants – Totaling ¥1,125,000 as PI or task leader across two major national projects in HIV and stem cell therapy (2022–2027).
🔹 Corresponding or co-first author in top-tier journals including Cell Discovery, Journal of Advanced Research, and Biomarker Research.
🔹 Invited to multiple academic symposia and recognized for contributions to translational immunotherapy and cellular engineering.
These accolades reflect his innovative thinking, scientific rigor, and clinical impact. 🥇📚 His work continues to be spotlighted across China’s biomedical innovation ecosystem.

📚 Top Noted Publications

Dr. Liao has authored/co-authored several impactful publications. Highlights:

1. Novel mRNA-Engineered Fully Human CAR-T Cells Targeting AXL in Solid Tumors

Journal: Biomedicines
Year: 2025
Cited by: 4
Summary:

  • Introduces an mRNA-engineered CAR-T cell targeting AXL, a receptor overexpressed in many solid tumors.

  • Uses a fully human scFv to reduce immunogenicity.

  • Demonstrates promising anti-tumor effects in preclinical solid tumor models, with transient CAR expression for improved safety.

2. Safe CAR-T: Shedding Light on CAR-Related T-cell Malignancies

Journal: EMBO Molecular Medicine
Year: 2025
Cited by: 7
Summary:

  • Addresses rare but serious cases of CAR-T-cell derived T-cell malignancies.

  • Explores the integration of CAR constructs into oncogenes as a potential risk.

  • Discusses safer vector systems and genomic insertion site monitoring.

3. Efficacy and Safety of M10 CAR-T Cells in HIV-1-Infected Patients

Journal: Cell Discovery
Year: 2024
Cited by: 18
Summary:

  • Describes M10 CAR-T cells engineered to target HIV-1-infected cells.

  • First-in-human data showed viral suppression and CD4+ T-cell recovery.

  • Provides early evidence for CAR-T application in chronic viral infections.

4. Biomarkers for Predicting CAR-T Efficacy and Detection Methods

Journal: iLABMED
Year: 2024
Cited by: 6
Summary:

  • Reviews current predictive biomarkers (e.g., tumor burden, cytokine profiles, T-cell exhaustion markers).

  • Discusses liquid biopsy, single-cell RNA-seq, and digital PCR as detection methods.

  • Emphasizes personalized CAR-T strategies using biomarker profiling.

5. Mouse Model for Evaluating CAR-T On-Target Toxicity

Journal: Journal of Advanced Research
Year: 2023
Cited by: 11
Summary:

  • Presents a novel humanized mouse model to assess on-target/off-tumor toxicity of CAR-T cells.

  • Demonstrates the importance of tissue-specific antigen expression in predicting adverse effects.

  • Tool for preclinical safety validation.

6. Hypoxia-Inducible CAR-T Cells (HiTA System)

Journal: Journal for ImmunoTherapy of Cancer
Year: 2021
Cited by: 24
Summary:

  • Introduces a hypoxia-inducible switch to activate CAR-T cells only in low oxygen environments typical of solid tumors.

  • Reduces systemic toxicity while maintaining anti-tumor efficacy.

  • Demonstrates improved safety in vivo with retained tumor-killing activity.

7. PD-L1 Chimeric Receptor Improves Efficacy in Solid Tumors

Journal: Biomarker Research
Year: 2020
Cited by: 27
Summary:

  • Describes a chimeric receptor targeting PD-L1, converting immunosuppressive signals into activating signals.

  • Enhances CAR-T function in immunosuppressive microenvironments.

  • Synergistic potential with checkpoint inhibitors.

8. HiCAR for Selective Tumor Killing

Journal: Biomarker Research
Year: 2020
Cited by: 21
Summary:

  • Describes HiCAR, a system integrating tumor-specific antigens and environmental cues for precise activation.

  • Uses dual-input logic for increased specificity and reduced toxicity.

  • Aimed at improving solid tumor selectivity of CAR-T therapies.

Conclusion 

Dr. Qibin Liao is highly suitable for the Best Researcher Award. His work on CAR-T innovations for both cancer and HIV is pioneering, impactful, and clinically relevant. The blend of scientific innovation, clinical translation, and strong funding/publication record positions him among the top emerging researchers in biomedical science in China.